← Russell 3000 cross-section

OVID Ovid Therapeutics Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$558m
Revenue TTM
$2m
Net income TTM
$-34m
Free cash flow
Composite score
Sector rank
#2355

Valuation

P / E
EV / EBITDA
EV / sales
278.2
FCF yield
Earnings yield vs 10-yr
-10.92pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-2,178.9%
EBITDA margin
-3,681.4%
ROE
-16.4%
ROIC
-63.0%
Revenue growth
-76.2%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Since inception, the Company has generated its revenue primarily from the Company’s royalty, license and termination agreement (“RLT Agreement”) with Takeda Pharmaceutical Company Limited (“Takeda”). In consideration for the rights granted to the Company under the Northwestern Agreement, the Company is required to pay to Northwestern up to an aggregate of $ 5.3 million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patent Rights, and upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percen …Ovid Therapeutics Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →